Nitrogen-linked derivatives of benzisoxazolesulfonamide for the treatment of cancer

Claims

1. Compound of formula (I): or a pharmaceutically acceptable salt thereof, where R 1 represents hydrogen, methoxy or fluorine; R 2 represents hydrogen or methoxy, provided that R 1 and R 2 both are not hydrogen, also provided that R 1 and R 2 both are non-methoxy; Ring A is C4-C5 cycloalkyl, 4-6 membered heterocycloalkyl, or 5-10 membered heteroaryl, where the point of attachment is on a carbon atom; R 3represents hydrogen, halogen, C1-C4 alkyl, CH2OCH3, methoxy, -C(O)OH, -C(O)OCH3, C3-C5 cycloalkyl, 4-6-membered heterocycloalkyl or benzyl, wherein C1-C4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, methoxy is optionally substituted with one, two or three fluorine atoms, and C3-C5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 represents hydrogen or C1-C3 alkyl optionally substituted with -OH; R 5 represents hydrogen, halogen, cyano, C1-C3 alkyl or -C(O)NH2; Ring B is C3-C6 cycloalkyl, C6-C 10 aryl or 5-10-membered heteroaryl; R 6 represents hydrogen, halogen, C1-C4 alkyl, -O-(C1-C4 alkyl) or -O-(C3-C5 cycloalkyl), where -O-(C1-C4 alkyl) is optionally substituted with one, two or three fluorine atoms; R 7 represents hydrogen, C1-C4 alkyl or methoxy; R 8represents hydrogen, halogen, cyano, C1-C4 alkyl, methoxy, phenyl, - (CHR 11 ) n -4-8-membered heterocycloalkyl, 5-8-membered heteroaryl, 9-10-membered heteroaryl, -C(O)NR 12 R 13 , N(CH3) (4-5-membered heterocycloalkyl) or -O-phenyl, where C1-C4 alkyl is optionally substituted with one or two methoxy substituents, -N(R 14 )(R 15 ) or one, two or three fluorine atoms, where phenyl is optionally substituted with methoxy, where -(CHR 11 ) n -4-8-membered heterocycloalkyl optionally substituted with one, two or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF2, -CF3, -CH2CHF2, -CH2CF3, methoxy, 4-6-membered heterocycloalkyl and one or two fluorine atoms, where the 5-8-membered heteroaryl is optionally substituted with oxo, cyano, methyl, -[CH(R 16 )] р[N(CH3)2] or 6-membered heterocycloalkyl which is optionally substituted with methyl, wherein the 9-10-membered heteroaryl is optionally substituted with methyl, where -C(O)NR 12 R 13 optionally substituted by one or two fluorine atoms, and where -O-phenyl is optionally substituted with fluorine, methyl or methoxy; R 9 is hydrogen or fluorine; R 10 represents hydrogen or C 1-3 alkyl; R 11 represents hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH2)5NH2 or -(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrazine)-CH3; R 13 represents hydrogen or C 1-2 alkyl; where if R 12 represents C 1-3 alkyl and R 13 represents C 1-2 alkyl, R 12 and R 13may be taken together with the nitrogen to which they are attached to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; each R 14 and R 15 independently represents methyl or ethyl; R 16 represents hydrogen or methyl; n is 0 or 1; and p is equal to 0 or 1.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the group consisting of cyclobutyl, cyclopentyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, imidazolyl, isoxazolyl, oxazolyl, 1-oxa-2,4-diazolyl, triazolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2-b]pyrazolyl] and 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl.

3. Compound of formula (II): or a pharmaceutically acceptable salt thereof, where R 3 represents hydrogen, halogen, C1-C4 alkyl, -CH2OCH3, methoxy, -C(O)OH, -C(O)OCH3, C3-C5 cycloalkyl, 4-6-membered heterocycloalkyl or benzyl, wherein C1-C4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, methoxy is optionally substituted with one, two or three fluorine atoms, and C3-C5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 represents hydrogen or C1-C3 alkyl optionally substituted with -OH; R 5 represents hydrogen, halogen, cyano, C1-C3 alkyl or -C(O)NH2; Ring B is C3-C6 cycloalkyl, C6-C 10 aryl or 5-10-membered heteroaryl; R 6 represents hydrogen, halogen, C1-C4 alkyl, -O-(C1-C4 alkyl) or -O-(C3-C5 cycloalkyl), where -O-(C1-C4 alkyl) is optionally substituted with one, two or three fluorine atoms; R7 represents hydrogen, C1-C4 alkyl or methoxy; R 8 represents hydrogen, halogen, cyano, C1-C4 alkyl, methoxy, phenyl, - (CHR 11 ) n -4-8-membered heterocycloalkyl, 5-8-membered heteroaryl, 9-10-membered heteroaryl, -C(O)NR 12 R 13 , -N(CH3) (4-5-membered heterocycloalkyl) or -O-phenyl, where C1-C4 alkyl is optionally substituted with one or two methoxy substituents, -N(R 14 )(R 15 ) or one, two or three fluorine atoms, where phenyl is optionally substituted with methoxy, where -(CHR 11 ) n -4-8-membered heterocycloalkyl optionally substituted with one, two or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF2, -CF3, -CH2CHF2, -CH2CF3, methoxy, 4-6-membered heterocycloalkyl and one or two fluorine atoms, where the 5-8-membered heteroaryl is optionally substituted with oxo, cyano, methyl, -[CH(R 16)] р [N(CH3)2] or 6-membered heterocycloalkyl which is optionally substituted with methyl, wherein the 9-10-membered heteroaryl is optionally substituted with methyl, where -C(O)NR 12 R 13 optionally substituted by one or two fluorine atoms, and where -O-phenyl is optionally substituted with fluorine, methyl or methoxy; R 9 is hydrogen or fluorine; R 10 represents hydrogen or C 1-3 alkyl; R 11 represents hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH2)5NH2 or -(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrazine)-CH3; R 13 represents hydrogen or C 1-2 alkyl; where if R 12 represents C 1-3 alkyl and R 13 represents C 1-2 alkyl, R 12 and R 13may be taken together with the nitrogen to which they are attached to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; each R 14 and R 15 independently represents methyl or ethyl; R 16 represents hydrogen or methyl; n is 0 or 1; and p is equal to 0 or 1.

4. A compound according to any one of claims 1-3 or a pharmaceutically acceptable salt thereof, wherein Ring B is selected from the group consisting of cyclopropyl, 1,2,3,4-tetrahydronaphthyl, naphthyl, chromanyl, isochromanyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, pyrazolyl, pyrimidinyl, quinolinyl and indazolyl.

5. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, having formula (III): or a pharmaceutically acceptable salt thereof, where R 3represents hydrogen, halogen, C1-C4 alkyl, -CH2OCH3, methoxy, -C(O)OH, -C(O)OCH3, C3-C5 cycloalkyl, 4-6-membered heterocycloalkyl or benzyl, wherein C1-C4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, methoxy is optionally substituted with one, two or three fluorine atoms, and C3-C5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 represents hydrogen or C1-C3 alkyl optionally substituted with -OH; R 5 represents hydrogen, halogen, cyano, C1-C3 alkyl or -C(O)NH2; R 6 represents hydrogen, halogen, C1-C4 alkyl, -O-(C1-C4 alkyl) or -O-(C3-C5 cycloalkyl), where -O-(C1-C4 alkyl) is optionally substituted with one, two or three fluorine atoms; R 7 represents hydrogen, C1-C4 alkyl or methoxy; R 8 represents hydrogen, halogen, cyano, C1-C4 alkyl, methoxy, phenyl, -(CHR 11 ) n-4-8-membered heterocycloalkyl, 5-8-membered heteroaryl, 9-10-membered heteroaryl, -C(O)NR 12 R 13 , -N(CH3) (4-5-membered heterocycloalkyl) or -O-phenyl, where C1-C4 alkyl is optionally substituted with one or two methoxy substituents, -N(R 14 )(R 15 ) or one, two or three fluorine atoms, where phenyl is optionally substituted with methoxy, where -(CHR 11 ) n -4-8-membered heterocycloalkyl optionally substituted with one, two or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF2, -CF3, -CH2CHF2, -CH2CF3, methoxy, 4-6-membered heterocycloalkyl and one or two fluorine atoms, where the 5-8-membered heteroaryl is optionally substituted with oxo, cyano, methyl, -[CH(R 16 )] р [N(CH3)2] or 6-membered heterocycloalkyl which is optionally substituted with methyl, wherein the 9-10-membered heteroaryl is optionally substituted with methyl, where -C(O)NR12 R 13 optionally substituted by one or two fluorine atoms, and where -O-phenyl is optionally substituted with fluorine, methyl or methoxy; R 9 is hydrogen or fluorine; R 10 represents hydrogen or C 1-3 alkyl; R 11 represents hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH2)5NH2 or -(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrazine)-CH3; R 13 represents hydrogen or C 1-2 alkyl; where if R 12 represents C 1-3 alkyl and R 13 represents C 1-2 alkyl, R 12 and R 13 may be taken together with the nitrogen to which they are attached to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; each R 14 and R 15independently represents methyl or ethyl; R 16 represents hydrogen or methyl; n is 0 or 1; and p is equal to 0 or 1.

6. A compound according to any one of paragraphs 1-5 or a pharmaceutically acceptable salt thereof, where R 6 is methoxy, R 7 is methoxy, R 8 represents hydrogen and R 9 is hydrogen.

7. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, having formula (IV): or a pharmaceutically acceptable salt thereof, where R 3represents hydrogen, halogen, C1-C4 alkyl, -CH2OCH3, methoxy, -C(O)OH, -C(O)OCH3, C3-C5 cycloalkyl, 4-6-membered heterocycloalkyl or benzyl, wherein C1-C4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, methoxy is optionally substituted with one, two or three fluorine atoms, and C3-C5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 represents hydrogen or C1-C3 alkyl optionally substituted with -OH; R 5 represents hydrogen, halogen, cyano, C1-C3 alkyl or -C(O)NH2; R 6 represents hydrogen, halogen, C1-C4 alkyl, -O-(C1-C4 alkyl) or -O-(C3-C5 cycloalkyl), where -O-(C1-C4 alkyl) is optionally substituted with one, two or three fluorine atoms; R 7 represents hydrogen, C1-C4 alkyl or methoxy; R 8 represents hydrogen, halogen, cyano, C1-C4 alkyl, methoxy, phenyl, -(CHR 11 ) n-4-8-membered heterocycloalkyl, 5-8-membered heteroaryl, 9-10-membered heteroaryl, -C(O)NR 12 R 13 , N(CH3) (4-5-membered heterocycloalkyl) or -O-phenyl, where C1-C4 alkyl is optionally substituted with one or two methoxy substituents, -N(R 14 )(R 15 ) or one, two or three fluorine atoms, where phenyl is optionally substituted with methoxy, where -(CHR 11 ) n -4-8-membered heterocycloalkyl optionally substituted with one, two or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF2, -CF3, -CH2CHF2, -CH2CF3, methoxy, 4-6-membered heterocycloalkyl and one or two fluorine atoms, where the 5-8-membered heteroaryl is optionally substituted with oxo, cyano, methyl, -[CH(R 16 )] р [N(CH3)2] or 6-membered heterocycloalkyl which is optionally substituted with methyl, wherein the 9-10-membered heteroaryl is optionally substituted with methyl, where -C(O)NR12 R 13 optionally substituted by one or two fluorine atoms, and where -O-phenyl is optionally substituted with fluorine, methyl or methoxy; R 11 represents hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH2)5NH2 or -(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrazine)-CH3; R 13 represents hydrogen or C 1-2 alkyl; where if R 12 represents C 1-3 alkyl and R 13 represents C 1-2 alkyl, R 12 and R 13 may be taken together with the nitrogen to which they are attached to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; each R 14 and R 15 independently represents methyl or ethyl; R 16 represents hydrogen or methyl; n is 0 or 1; and p is equal to 0 or 1.

8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, having the formula (V): or a pharmaceutically acceptable salt thereof, where R 3 represents hydrogen, halogen, C1-C4 alkyl, -CH2OCH3, methoxy, -C(O)OH, -C(O)OCH3, C3-C5 cycloalkyl, 4-6-membered heterocycloalkyl or benzyl, wherein C1-C4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, methoxy is optionally substituted with one, two or three fluorine atoms, and C3-C5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 represents hydrogen or C1-C3 alkyl optionally substituted with -OH; R 5 represents hydrogen, halogen, cyano, C1-C3 alkyl or -C(O)NH2; R 6represents hydrogen, halogen, C1-C4 alkyl, -O-(C1-C4 alkyl) or -O-(C3-C5 cycloalkyl), where -O-(C1-C4 alkyl) is optionally substituted with one, two or three fluorine atoms; R 7 represents hydrogen, C1-C4 alkyl or methoxy; R 8 represents hydrogen, halogen, cyano, C1-C4 alkyl, methoxy, phenyl, -(CHR 11 ) n -4-8-membered heterocycloalkyl, 5-8-membered heteroaryl, 9-10-membered heteroaryl, -C(O)NR 12 R 13 , -N(CH3) (4-5-membered heterocycloalkyl) or -O-phenyl, where C1-C4 alkyl is optionally substituted with one or two methoxy substituents, -N(R 14 )(R 15 ) or one, two or three fluorine atoms, where phenyl is optionally substituted with methoxy, where -(CHR 11 ) n-4-8-membered heterocycloalkyl optionally substituted with one, two or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF2, -CF3, -CH2CHF3, -CH2CF3, methoxy, 4-6-membered heterocycloalkyl and one or two fluorine atoms, where the 5-8-membered heteroaryl is optionally substituted with oxo, cyano, methyl, -[CH(R 16 )] р [N(CH3)2] or 6-membered heterocycloalkyl which is optionally substituted with methyl, wherein the 9-10-membered heteroaryl is optionally substituted with methyl, where -C(O)NR 12 R 13 optionally substituted by one or two fluorine atoms, and where -O-phenyl is optionally substituted with fluorine, methyl or methoxy; R 11 represents hydrogen or methyl; R 12 represents hydrogen, C 1-3 alkyl, -(CH2)5NH2 or -(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrazine)-CH3; R 13 represents hydrogen or C 1-2 alkyl; where if R 12 represents C 1-3 alkyl and R 13 represents C 1-2 alkyl, R 12 and R 13 may be taken together with the nitrogen to which they are attached to form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; each R 14 and R 15 independently represents methyl or ethyl; R 16 represents hydrogen or methyl; n is 0 or 1; and p is equal to 0 or 1.

9. A compound according to any one of paragraphs 1-8 or a pharmaceutically acceptable salt thereof, where R 3 represents hydrogen, chlorine, C1-C4 alkyl, -CHF2, -CF3, -CF2CH3, -CH2-CF3, -CH2OCH3, methoxy, -O-CHF2, -C(O)OH, -C(O)OCH3, bicyclo[1,1,1]pentan-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl or benzyl, where C1-C4 alkyl is optionally substituted with -OH, and where cyclopropyl is optionally substituted with methyl or two fluorine atoms.

10. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, where R 3 is cyclopropyl.

11. A compound according to any one of claims 1-10 or a pharmaceutically acceptable salt thereof, where R 4 represents hydrogen, methyl, ethyl, or isopropyl.

12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof, where R 4 is hydrogen.

13. A compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, where R 5 represents hydrogen, fluorine, cyano, methyl, ethyl, or -C(O)NH2.

14. The compound according to claim 13 or a pharmaceutically acceptable salt thereof, where R 5 is hydrogen.

15. A compound according to any one of claims 1-8 or a pharmaceutically acceptable salt thereof, where R 3 is cyclopropyl, R 4 represents hydrogen and R 5is hydrogen.

16. A compound according to any one of paragraphs 1-5 and 7-15 or a pharmaceutically acceptable salt thereof, where R 6 represents hydrogen, bromine, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, -O-isopropyl, -O-CH2CHF3, -O-CF3, -O-cyclobutyl or -O-cyclopropyl.

17. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, where R 6 is a methoxy.

18. A compound according to any one of paragraphs 1-5 and 7-15 or a pharmaceutically acceptable salt thereof, where R 7 represents hydrogen, methyl, ethyl, or methoxy.

19. The compound according to claim 18 or a pharmaceutically acceptable salt thereof, where R 7 is a methoxy.

20. The compound according to claim 18 or a pharmaceutically acceptable salt thereof, where R 7 is hydrogen.

21. A compound according to any one of paragraphs 1-5 and 7-15 or a pharmaceutically acceptable salt thereof, where R 8represents hydrogen, chlorine, fluorine, methyl, ethyl, propyl, -CHF2, -CF3, -CH2OCH3, -CH(CH3)(OCH3), -C(CH3)2(OCH3), -CH(OCH3) (CH2OCH3), -CH2-N(CH3)2, methoxy, phenyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, dioxanyl, morpholinyl, -CH(CH3)-azetidinyl, -CH2-pyrrolidinyl, -CH(CH3)-morpholinyl, azaspiro[3.4]octanyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, hexahydropyrido[3,4-d]pyrimidinyl, -C(O)-azetidinyl, -C(O)-pyrrolidinyl, -C(O)-piperidinyl, -C(O)NH(CH2)5NH2, -C(O)NH(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrazine)-CH3, -N(CH3)(oxetanyl), -N(CH3)(tetrahydrofuranyl) or -O-phenyl, where phenyl is optionally substituted with methoxy, wherein azetidinyl is optionally substituted with methoxy, fluorine or tetrahydrofuran, wherein pyrrolidinyl is optionally substituted with one substituent selected from oxo, methyl, ethyl, -CH2CHF2, methoxy, tetrahydrofuran and fluoro, or with two or three substituents independently selected from oxo, methyl and fluoro, where dioxanyl is optionally substituted with two methyl substituents, wherein piperidinyl is optionally substituted with one substituent selected from methyl, ethyl, -CH2CHF2, -CH2CF3, oxetanyl and tetrahydrofuran, or two or three substituents independently selected from methyl and one or two fluorine atoms, wherein piperazine is optionally substituted with methyl or two substituents selected from oxo and methyl, where morpholinyl is optionally substituted with methyl or ethyl, where -CH2-azetidinyl is optionally substituted with methyl or one or two fluorine atoms, where -CH(CH3)-azetidinyl is optionally substituted with one fluorine atom, where -CH2-pyrrolidinyl is optionally substituted with -CHF2, -CF3, two methyl substituents, or one or two fluorine atoms, where -CH2-piperidinyl is optionally substituted with methyl, methoxy or one or two fluorine atoms, where pyrazolyl is optionally substituted with methyl, wherein triazolyl is optionally substituted with methyl, where imidazolyl is optionally substituted with methyl, wherein pyridinyl is optionally substituted with one or two substituents selected from methyl and oxo, where pyrazinyl is optionally substituted with methyl or -N(CH3)2, wherein pyrimidinyl is optionally substituted with methyl, cyano, -CH2[N(CH3)2], -N(CH3)2, -CH(CH3)[N(CH3)2] or methyl substituted piperazinyl, wherein pyridazinyl is optionally substituted with oxo or methyl, wherein hexahydropyrido[3,4-d]pyrimidinyl is optionally substituted with methyl, where -C(O)-azetidinyl, -C(O)-pyrrolidinyl, and -C(O)-piperidinyl are each independently optionally substituted with one or two fluorine atoms, and where -O-phenyl is optionally substituted by methyl or fluorine.

22. A compound selected from the group consisting of or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

23. The compound of claim 22 or a tautomer thereof or a pharmaceutically acceptable salt of the compound or a tautomer thereof, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

24. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

25. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

26. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

27. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

28. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

29. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

30. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.

31. The compound according to claim 22, its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer, wherein the compound is: or its tautomer or a pharmaceutically acceptable salt of the compound or its tautomer.